The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/100 - 1/1000.
Use at an assay dependent dilution.
RelevanceEpstein Barr virus (EBV) is a member of the herpesvirus family and one of the most common human viruses. Most people become infected with EBV during their lives. Primary infections usually results in infectious mononucleosis (glandular fever) but the virus can also lay dormant in B lymphocytes and when reactivated become associated with more serious disease such as Burkitt's lymphoma, nasopharyngeal carcinoma and Hodgkin's disease.
EBV latently infects B lymphocytes. Infected B cells express EBV nuclear antigens and latent proteins LMP1, LMP2A and LMP2B. LMP2A forms aggregates in the plasma membranes of B lymphocytes, where it functions as a negative regulator of the Src and Syk protein tyrosine kinases.
Studies show that LMP2A blocks B-cell receptor (BCR) signal transduction in EBV immortalized B cells in vitro and may play an important role in maintaining a latent EBV infection within the peripheral blood B cells of infected individuals.
EBV latent membrane protein 2A antibody
Epstein Barr virus antibody
Human Herpesvirus 4 antibody
Latent membrane protein 2 antibody
Terminal protein antibody
References for Anti-EBV LMP2A antibody [15F9] (ab59028)
This product has been referenced in:
Quan L et al. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLoS One10:e0136476 (2015).
Read more (PubMed: 26361042) »
Cohen M et al. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment. Int J Cancer132:1572-80 (2013).
Read more (PubMed: 22987474) »